Clinical Trial Update: A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/II clinical study evaluating HRS-1167 in combination with bevacizumab for recurrent ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• HRS-1167

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Recurrent Ovarian Cancer | Phase 1, Phase 2 | Status: UNKNOWN